Tan Ruyi, Abasszade Joshua Haron, Dhillon Hardesh, Kuan Chih Chien, Worland Thomas, Tabatabai Shireen
Department of Gastroenterology and Hepatology, Monash Health, Melbourne, VIC, Australia.
Department of Anatomical Pathology, Monash Health, Melbourne, VIC, Australia.
Case Rep Gastroenterol. 2024 Apr 25;18(1):238-243. doi: 10.1159/000538552. eCollection 2024 Jan-Dec.
Olmesartan, an angiotensin II receptor antagonist, is associated with an uncommon complication of enteropathy that presents insidiously, usually months to years after initial commencement of anti-hypertensive therapy which can be dose-dependent. It has a variable spectrum of clinical presentation but commonly presents as a moderate to severe malabsorptive process with potential severe complications related to poor end-organ perfusion. Lymphocytic gastritis and microscopic colitis are often noted in patients presenting with olmesartan-induced enteropathy; however, hepatic involvement has been less frequently observed.
We illustrate a case of a 43-year-old female presenting with 2 weeks of profuse non-bloody diarrhea in the context of olmesartan enteropathy which was complicated by an acute severe ischemic and enteropathic hepatopathy.
Our case prompts clinicians to maintain a high index of suspicion in cases presenting with a seronegative enteropathy and concurrent acute liver injury while on olmesartan therapy. Cessation of olmesartan therapy resulted in prompt resolution of diarrheal symptoms and normalization of the acute transaminitis on subsequent three-week follow-up.
奥美沙坦是一种血管紧张素II受体拮抗剂,与一种罕见的肠病并发症有关,这种并发症隐匿出现,通常在开始抗高血压治疗数月至数年之后,且可能与剂量有关。其临床表现多样,但通常表现为中度至重度吸收不良过程,并伴有与终末器官灌注不良相关的潜在严重并发症。淋巴细胞性胃炎和显微镜下结肠炎在奥美沙坦诱导的肠病患者中常可见到;然而,肝脏受累情况较少见。
我们阐述了一例43岁女性病例,该患者在奥美沙坦肠病背景下出现了2周的大量非血性腹泻,并并发急性严重缺血性和肠病性肝病。
我们的病例提示临床医生,对于在接受奥美沙坦治疗时出现血清阴性肠病并伴有急性肝损伤的病例,应保持高度怀疑。停用奥美沙坦治疗后,腹泻症状迅速缓解,在随后的三周随访中急性转氨酶升高恢复正常。